A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results

被引：38
|
作者：
Zeidan, Amer M. [1 ,2 ]
DeAngelo, Daniel J. [3 ]
Palmer, Jeanne M. [4 ]
Seet, Christopher S. [5 ]
Tallman, Martin S. [6 ]
Wei, Xin [7 ]
Li, Ying Fei [8 ]
Hock, Nanette [9 ]
Burgess, Michael R. [9 ]
Hege, Kristen [9 ]
Stock, Wendy [10 ]
机构：
[1] Yale Univ, New Haven, CT USA
[2] Yale Canc Ctr, New Haven, CT USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Mayo Clin, Phoenix, AZ USA
[5] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Los Angeles, CA 90095 USA
[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[7] Celgene Corp, Berkeley, NJ USA
[8] Celgene Corp, Summit, NJ USA
[9] Celgene Corp, San Francisco, CA USA
[10] Univ Chicago Med, Chicago, IL USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-125363
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1320
引用
收藏
页数：6
相关论文
共 50 条
  • [21] Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): Final Results from a Phase 1/2 Study
    Halpern, Anna B.
    Buckley, Sarah A.
    Othus, Megan
    Huebner, Emily M.
    Orlowski, Kaysey F.
    Scott, Bart L.
    Perdue, Andrea M.
    Smith, Heather A.
    Becker, Pamela S.
    Hendrie, Paul C.
    Cassone, Stephanie
    Chen, Tara L.
    Stirewalt, Derek L.
    Estey, Elihu H.
    Walter, Roland B.
    BLOOD, 2016, 128 (22)
  • [22] A phase I/II trial of combination of PKC412 and 5-azacytidine (AZA) for the treatment of patients with refractory or relapsed (R/R) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
    Nazha, Aziz
    Kantarjian, Hagop
    Borthakur, Gautam
    Kadia, Tapan M.
    Faderl, Stefan
    Ravandi, Farhad
    Estrov, Zeev
    Jabbour, Elias
    Quintas-Cardama, Alfonso
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome
    Assi, Rita
    Kantarjian, Hagop M.
    Kadia, Tapan M.
    Pemmaraju, Naveen
    Jabbour, Elias
    Jain, Nitin
    Daver, Naval
    Estrov, Zeev
    Uehara, Taisuke
    Owa, Takashi
    Cortes, Jorge E.
    Borthakur, Gautam
    CANCER, 2018, 124 (13) : 2758 - 2765
  • [24] Evaluation of ON01910.Na In Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I Study
    Silverman, Lewis R.
    Navada, Shyamala C.
    Odchimar-Reissig, Rosalie
    Najfeld, Vesna
    Ohnuma, Takao
    Wilhelm, Francois
    Reddy, E. Premkumar
    Holland, James F.
    BLOOD, 2010, 116 (21) : 1214 - 1214
  • [25] A Phase II Study of Lenalidomide Alone in Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes With Chromosome 5 Abnormalities
    Chen, Yiming
    Kantarjian, Hagop
    Estrov, Zeev
    Faderl, Stefan
    Ravandi, Farhad
    Rey, Kristy
    Cortes, Jorge
    Borthakur, Gautam
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2012, 12 (05): : 341 - 344
  • [26] Phase I study of UCN-01 and ara-C for patients with refractory or relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
    Cortes, J
    Plunkett, WK
    Estey, EH
    Keating, MJ
    Madden, T
    Sampath, D
    Faderl, S
    Beran, M
    Dancey, J
    Kantarjian, HM
    BLOOD, 2001, 98 (11) : 211B - 211B
  • [27] A Phase 1 Study of WU-NK-101 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
    Cashen, Amanda F.
    Liu, Hongtao
    Al Malki, Monzr M.
    Zeidner, Joshua F.
    Foster, Matthew C.
    Pannunzio, Angela
    Ramsey, Brett
    Baughman, Jan
    Muth, John
    Bakkacha, Ouiam
    McNulty, Eileen
    Jacobs, Kenneth
    Davidson-Moncada, Jan K.
    Wei, Andrew H.
    BLOOD, 2022, 140 : 12740 - 12741
  • [28] A Phase I Study of IGN523, a Novel Anti-CD98 Monoclonal Antibody in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
    Bixby, Dale
    Wieduwilt, Matthew J.
    Akard, Luke Paul
    Khoury, H. Jean
    Becker, Pamela S.
    Van Der Horst, Edward H.
    Ho, William
    Cortes, Jorge E.
    BLOOD, 2015, 126 (23)
  • [29] Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML
    Daver, Naval
    Senapati, Jayastu
    Maiti, Abhishek
    Loghavi, Sanam
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Pemmaraju, Naveen
    Jabbour, Elias
    Montalban-Bravo, Guillermo
    Tang, Guilin
    Sasaki, Koji
    Borthakur, Gautam
    Yilmaz, Musa
    Alvarez, Joie
    Pierce, Sherry A.
    Gonzalez, Graciela M. Nogueras
    Ning, Jing
    Issa, Ghayas C.
    Andreeff, Michael
    Abbas, Hussein A.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    BLOOD, 2022, 140
  • [30] Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
    Attar, Eyal C.
    Amrein, Philip C.
    Fraser, James W.
    Fathi, Amir T.
    McAfee, Steven
    Wadleigh, Martha
    DeAngelo, Daniel J.
    Steensma, David P.
    Stone, Richard M.
    Foster, Julia
    Neuberg, Donna
    Ballen, Karen K.
    LEUKEMIA RESEARCH, 2013, 37 (09) : 1016 - 1020
12345